Zhang Yong, Qi Yalong, Wang Axiang, Ma Baozhen, Fu Xiaomin, Zhao Lingdi, Gao Quanli
Department of Biotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, People's Republic of China.
Onco Targets Ther. 2017 Sep 22;10:4687-4690. doi: 10.2147/OTT.S147714. eCollection 2017.
Endometrial cancer is the most prevalent gynecological malignancy in the USA, and its treatment involves surgery, chemotherapy, and radiotherapy. Cytokine-induced killer (CIK) cell-based treatments have shown antitumor activity against several solid tumors. However, to the best of our knowledge, there are no reports yet of CIK immunotherapy in the treatment of endometrial cancer, and consequently, little is known about its efficacy and safety. Here, we report a case of an endometrial cancer patient receiving a combination treatment with CIK cells immunotherapy and chemotherapy. Assessment for clinical features was carried out after every two cycles of CIK immunotherapy and chemotherapy. No severe toxicity was observed after infusion of CIK cells. After 4 cycles of treatment, the patient achieved complete response and showed elevated Karnofsky Performance Status scores with an overall survival time of 13.6 months. The combination therapy improved the quality of life and prolonged patient survival time, which suggested that CIK cell therapy might be a potentially beneficial option for endometrial cancer.
子宫内膜癌是美国最常见的妇科恶性肿瘤，其治疗方法包括手术、化疗和放疗。细胞因子诱导的杀伤（CIK）细胞治疗已显示出对多种实体瘤的抗肿瘤活性。然而，据我们所知，尚无关于CIK免疫疗法治疗子宫内膜癌的报道，因此，对其疗效和安全性知之甚少。在此，我们报告一例子宫内膜癌患者接受CIK细胞免疫疗法与化疗联合治疗的病例。在每两个周期的CIK免疫疗法和化疗后进行临床特征评估。输注CIK细胞后未观察到严重毒性。经过4个周期的治疗，患者达到完全缓解，卡诺夫斯基功能状态评分升高，总生存时间为13.6个月。联合治疗改善了生活质量，延长了患者生存时间，这表明CIK细胞治疗可能是子宫内膜癌的一种潜在有益选择。
